Skip to main content

Table 1 Characteristics of patients

From: Efficacy and safety of plasma exchange for Kawasaki disease with coronary artery dilatation

Patient Gender Age (months) BW (kg) Start of IVIG (day) Treatment before PE Dose of IVIG Period of PSL (day) Additional treatment of IVIG
1 M 7 7.5 6 ASA, PSL, IVIG × 3 1 g/kg × 2, 2 g/kg × 1 11–30
2 M 29 13.8 4 ASA, PSL, IVIG × 2 2 g/kg × 2 7.11
3 M 7 7.4 4 ASA, PSL, IVIG × 2 1 g/kg × 2 6–8 1 g/kg × 2 (days 9 and 10), 2 g/kg × 2 (day 11)
4 M 11 8.0 4 ASA, IVIG × 2 2 g/kg × 2
5 F 3 4.5 5 ASA, IVIG × 2 2 g/kg × 2 14–59 2 g/kg × 2 (days 14 and 18)
6 M 36 13.3 4 ASA, PSL, IVIG × 2 2 g/kg × 2 7,8 2 g/kg × 2 (day 13)
7 M 53 14.0 4 ASA, PSL, IVIG × 3 1 g/kg × 2, 2 g/kg × 1 6–8
8 M 17 10.2 4 PSL, IVIG × 2 2 g/kg × 2 6–27 2 g/kg × 2 (day 14)
9 F 12 11.9 21 ASA, PSL, IVIG × 1 1 g/kg × 1 4, 10, 11, 14
10 M 63 17.8 5 ASA, PSL, IVIG × 3 2 g/kg × 3 6, 8, 9 2 g/kg × 2 (days 10 and 20)
  1. BW body weight, ASA acetylsalicylic acid, PSL prednisolone, IVIG intravenous immunoglobulin infusion, PE plasma exchange
  2. Dose of IVIG: single dose × day